SEC Filing Summary for AIM ImmunoTech Inc.

This filing details a transaction by Thomas K Equels, CEO & President of AIM ImmunoTech Inc. On September 15, 2026, Mr. Equels acquired 22,000 shares of Common Stock at a price of $0.221 per share. Following this transaction, he holds a total of 91,822 shares. The transaction was reported on Form 4, filed on September 16, 2026. This transaction is classified as direct ownership.